BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Deals

  Takeda Augments IO Portfolio with Third Build-to-Buy Acquisition in a Year

  The planned acquisition will give Takeda full access to Adaptate’s antibody-based γδ T cell engager platform, which includes both pre-clinical and discovery assets.

  January 10, 2022

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Business

  Pfizer Triple-Partners for Future mRNA Vaccines and Genetic Medicines

  Around 40% of Pfizer’s portfolio was realized through partnerships, and Monday, the pharma giant announced three more collaborative deals.

  January 10, 2022

   · 

  2 min read

   · 

  Kate Goodwin
• 

  FDA

  Biocon Downplays Mysterious CRL for Insulin Biosimilar

  While Biocon intends to address the CRL, the company has not established a timeline for the resubmission of data and hopes that the FDA will rapidly review the BLA when it does submit the data.

  January 10, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Beach

  Sigyn Therapeutics: Calming and Preventing the Cytokine Storm

  Sigyn is not only trying to treat the inflammatory mediators that fuel sepsis; it wants to prevent the life-threatening event from occurring altogether.

  January 10, 2022

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Business

  Maze Therapeutics Nets $190M to Propel Precision Medicine Programs

  The company has produced a varied pipeline focused on the development of precision pharmacological treatments for nine different programs.

  January 10, 2022

   · 

  2 min read

   · 

  Kaylei Whalen
• 

  Drug Development

  Largest Phase III Hemophilia Gene Therapy Trial Yields Positive Results

  The results over the two-year evaluation period for its Phase III GENEr8-1 trial showed consistent clinical benefit from using valoctocogene roxaparvovec.

  January 10, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  FDA

  U.S. Averaging 700K New COVID-19 Cases Daily as Deltacron Revealed

  The U.S. averages more than 700,000 new COVID-19 cases per day. As of Saturday, there were 4.91M cases, more cases in seven days than in April, May, June, and July 2021 combined.

  January 10, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Moderna Surges into 2022 with Carisma CAR-M Partnership

  Moderna roared through 2021 on the strength of its COVID-19 vaccine and that momentum is continuing in 2022.

  January 10, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Bayer Strikes “Mammoth” CRISPR Deal to Bolster Cell and Gene Therapy

  Bayer and Mammoth Biosciences forged a strategic collaboration potentially valued at more than $1 billion. The partnership grants Bayer access to Mammoth’s CRISPR technology to develop in vivo gene-editing therapies.

  January 10, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  FDA Okays Idorsia Insomnia Drug, Giving Hope to the Sleep-Deprived

  The approval was based on data from a broad clinical program of 1,854 adults with insomnia conducted at more than 160 clinical sites in 18 countries.

  January 10, 2022

   · 

  2 min read

   · 

  Mark Terry